FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2522875414> ?p ?o ?g. }

• W2522875414 endingPage "3046" @default.
• W2522875414 startingPage "3041" @default.
• W2522875414 abstract "Due to the safety, convenience and efficacy of subcutaneous administration of bortezomib (scBor), it is becoming increasingly common to treat multiple myeloma (MM) using this treatment method. The current retrospective study suggested a lower incidence of peripheral neuropathy (PN) outcomes and superior efficacy following treatment with scBor combined with thalidomide and dexamethasone (VTD) in MM when compared with intravenous Bor (ivBor) treatment. The data of 81 patients from the Affiliated Hospital of Nantong University between September 2011 and February 2014 were analyzed, including 37 scBor and 44 ivBor patients administered a median (range) of 5.5 (3‑8) and 6 (3‑10) chemotherapy cycles, respectively. Adverse events (AEs) were assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for AEs, and response and progression were assessed by the International Myeloma Working Group criteria. Evidence of histopathology using transmission electron microscopy (TEM) was obtained from an in vivo model of adult Sprague Dawley (SD) rats. Following bortezomib‑based VTD chemotherapy, patients had achieved very good partial remission or demonstrated no significant difference between the scBor and ivBor treatment groups (75.6 vs. 84.1%, respectively; P=0.350). The 1‑year progression‑free survival (83.8 vs. 84.1%, scBor vs. ivBor; P=0.921) and 1‑year overall survival (OS) (91.9 vs. 90.9%, respectively; P=0.926) were also similar. PN rates of all the NCI grades were 51.3 and 61.3% (P=0.371); grade ≥2, 35.1 and 56.8% (P=0.052); and grade ≥3, 32.7 and 20.5% (P=0.015) in the subcutaneous and intravenous treatment groups, respectively, which suggests that severe PN may be less common following scBor treatment. There were no severe injection site reactions in the scBor‑treated group. The incidence of adverse events were comparable between the two groups, including thrombocytopenia, anemia, fatigue and gastrointestinal symptoms such as nausea and vomiting. Furthermore, TEM images of the SD rat sciatic nerves revealed that all rats suffered PN to varying degrees, except the control group, and that the PN of ivBor‑treated rats (in the presence and the absence of thalidomide) was more severe than that of scBor‑treated rats. It was concluded that a subcutaneous dose of bortezomib of 1.3 mg/m2 may result in a lower incidence and severity of PN, with equivalent efficacy, as a component of combination VTD chemotherapy." @default.
• W2522875414 created "2016-09-30" @default.
• W2522875414 creator A5033946832 @default.
• W2522875414 creator A5057287134 @default.
• W2522875414 creator A5077764073 @default.
• W2522875414 date "2016-09-21" @default.
• W2522875414 modified "2023-09-27" @default.
• W2522875414 title "Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma" @default.
• W2522875414 cites W1675440191 @default.
• W2522875414 cites W1906348670 @default.
• W2522875414 cites W1963909872 @default.
• W2522875414 cites W1987068734 @default.
• W2522875414 cites W1989740966 @default.
• W2522875414 cites W1992083467 @default.
• W2522875414 cites W1992376132 @default.
• W2522875414 cites W2023661149 @default.
• W2522875414 cites W2027923776 @default.
• W2522875414 cites W2035104247 @default.
• W2522875414 cites W2039923434 @default.
• W2522875414 cites W2044436186 @default.
• W2522875414 cites W2046561177 @default.
• W2522875414 cites W2066023632 @default.
• W2522875414 cites W2070790769 @default.
• W2522875414 cites W2072018052 @default.
• W2522875414 cites W2073185898 @default.
• W2522875414 cites W2096207943 @default.
• W2522875414 cites W2120474651 @default.
• W2522875414 cites W2150878522 @default.
• W2522875414 cites W2156813481 @default.
• W2522875414 cites W2163426652 @default.
• W2522875414 cites W2169183166 @default.
• W2522875414 cites W2230048083 @default.
• W2522875414 cites W2343425851 @default.
• W2522875414 cites W2417703859 @default.
• W2522875414 cites W2554414226 @default.
• W2522875414 doi "https://doi.org/10.3892/etm.2016.3738" @default.
• W2522875414 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5103742" @default.
• W2522875414 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27882113" @default.
• W2522875414 hasPublicationYear "2016" @default.
• W2522875414 type Work @default.
• W2522875414 sameAs 2522875414 @default.
• W2522875414 citedByCount "15" @default.
• W2522875414 countsByYear W25228754142017 @default.
• W2522875414 countsByYear W25228754142018 @default.
• W2522875414 countsByYear W25228754142019 @default.
• W2522875414 countsByYear W25228754142020 @default.
• W2522875414 countsByYear W25228754142021 @default.
• W2522875414 countsByYear W25228754142022 @default.
• W2522875414 crossrefType "journal-article" @default.
• W2522875414 hasAuthorship W2522875414A5033946832 @default.
• W2522875414 hasAuthorship W2522875414A5057287134 @default.
• W2522875414 hasAuthorship W2522875414A5077764073 @default.
• W2522875414 hasBestOaLocation W25228754141 @default.
• W2522875414 hasConcept C120665830 @default.
• W2522875414 hasConcept C121332964 @default.
• W2522875414 hasConcept C121608353 @default.
• W2522875414 hasConcept C126322002 @default.
• W2522875414 hasConcept C134018914 @default.
• W2522875414 hasConcept C141071460 @default.
• W2522875414 hasConcept C143998085 @default.
• W2522875414 hasConcept C197934379 @default.
• W2522875414 hasConcept C2776364478 @default.
• W2522875414 hasConcept C2776694085 @default.
• W2522875414 hasConcept C2777478702 @default.
• W2522875414 hasConcept C2777793932 @default.
• W2522875414 hasConcept C2779609412 @default.
• W2522875414 hasConcept C2779901536 @default.
• W2522875414 hasConcept C2780401358 @default.
• W2522875414 hasConcept C555293320 @default.
• W2522875414 hasConcept C61511704 @default.
• W2522875414 hasConcept C71924100 @default.
• W2522875414 hasConcept C90924648 @default.
• W2522875414 hasConceptScore W2522875414C120665830 @default.
• W2522875414 hasConceptScore W2522875414C121332964 @default.
• W2522875414 hasConceptScore W2522875414C121608353 @default.
• W2522875414 hasConceptScore W2522875414C126322002 @default.
• W2522875414 hasConceptScore W2522875414C134018914 @default.
• W2522875414 hasConceptScore W2522875414C141071460 @default.
• W2522875414 hasConceptScore W2522875414C143998085 @default.
• W2522875414 hasConceptScore W2522875414C197934379 @default.
• W2522875414 hasConceptScore W2522875414C2776364478 @default.
• W2522875414 hasConceptScore W2522875414C2776694085 @default.
• W2522875414 hasConceptScore W2522875414C2777478702 @default.
• W2522875414 hasConceptScore W2522875414C2777793932 @default.
• W2522875414 hasConceptScore W2522875414C2779609412 @default.
• W2522875414 hasConceptScore W2522875414C2779901536 @default.
• W2522875414 hasConceptScore W2522875414C2780401358 @default.
• W2522875414 hasConceptScore W2522875414C555293320 @default.
• W2522875414 hasConceptScore W2522875414C61511704 @default.
• W2522875414 hasConceptScore W2522875414C71924100 @default.
• W2522875414 hasConceptScore W2522875414C90924648 @default.
• W2522875414 hasIssue "5" @default.
• W2522875414 hasLocation W25228754141 @default.
• W2522875414 hasLocation W25228754142 @default.
• W2522875414 hasLocation W25228754143 @default.
• W2522875414 hasLocation W25228754144 @default.
• W2522875414 hasOpenAccess W2522875414 @default.
• W2522875414 hasPrimaryLocation W25228754141 @default.

• next